BR112023002225A2 - Método para tratar um distúrbio mediado pela ikaros e/ou aiolos - Google Patents
Método para tratar um distúrbio mediado pela ikaros e/ou aiolosInfo
- Publication number
- BR112023002225A2 BR112023002225A2 BR112023002225A BR112023002225A BR112023002225A2 BR 112023002225 A2 BR112023002225 A2 BR 112023002225A2 BR 112023002225 A BR112023002225 A BR 112023002225A BR 112023002225 A BR112023002225 A BR 112023002225A BR 112023002225 A2 BR112023002225 A2 BR 112023002225A2
- Authority
- BR
- Brazil
- Prior art keywords
- aiolos
- ikaros
- treatment
- disorder mediated
- mediated
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/499—Spiro-condensed pyrazines or piperazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
- C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Medicines Containing Plant Substances (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063063011P | 2020-08-07 | 2020-08-07 | |
| US202163173160P | 2021-04-09 | 2021-04-09 | |
| US202163212463P | 2021-06-18 | 2021-06-18 | |
| PCT/US2021/045000 WO2022032132A1 (en) | 2020-08-07 | 2021-08-06 | Advantageous therapies for disorders mediated by ikaros or aiolos |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112023002225A2 true BR112023002225A2 (pt) | 2023-03-07 |
Family
ID=80118544
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112023002225A BR112023002225A2 (pt) | 2020-08-07 | 2021-08-06 | Método para tratar um distúrbio mediado pela ikaros e/ou aiolos |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20230190760A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4192450A4 (cg-RX-API-DMAC7.html) |
| JP (2) | JP7846086B2 (cg-RX-API-DMAC7.html) |
| KR (1) | KR20230049678A (cg-RX-API-DMAC7.html) |
| CN (1) | CN116194438B (cg-RX-API-DMAC7.html) |
| AU (1) | AU2021322285B2 (cg-RX-API-DMAC7.html) |
| BR (1) | BR112023002225A2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3173658A1 (cg-RX-API-DMAC7.html) |
| IL (1) | IL300373A (cg-RX-API-DMAC7.html) |
| MX (1) | MX2023001545A (cg-RX-API-DMAC7.html) |
| TW (1) | TWI887465B (cg-RX-API-DMAC7.html) |
| WO (1) | WO2022032132A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4717317A3 (en) | 2017-06-20 | 2026-06-03 | C4 Therapeutics, Inc. | N/o-linked degrons and degronimers for protein degradation |
| KR102947433B1 (ko) * | 2019-04-12 | 2026-04-06 | 씨4 테라퓨틱스, 인코포레이티드 | 이카로스 및 아이올로스의 트리시클릭 분해제 |
| SMT202600194T1 (it) * | 2019-10-21 | 2026-05-12 | Celgene Corp | Combinazione di composti di 4-amminoisoindolin-1,3-dione sostituiti e di secondi agenti attivi per l'uso nel trattamento di una condizione maligna ematologica |
| US11807620B2 (en) | 2020-02-21 | 2023-11-07 | Plexium, Inc. | Quinazolinone compounds and related compounds |
| CN119823124A (zh) | 2020-03-05 | 2025-04-15 | C4医药公司 | 用于brd9的靶向降解的化合物 |
| CA3194351A1 (en) * | 2020-10-14 | 2022-04-21 | Christopher G. Nasveschuk | Tricyclic compounds to degrade neosubstrates for medical therapy |
| JP7863100B2 (ja) * | 2020-10-14 | 2026-05-20 | シーフォー セラピューティクス, インコーポレイテッド | Ikzf2又はikzf4を分解する三環式リガンド |
| JP7807110B2 (ja) * | 2021-08-27 | 2026-01-27 | ハンチョウ グルビオ ファーマシューティカル カンパニー,リミティド | イソインドリノン化合物およびその使用 |
| JP2025505687A (ja) * | 2022-02-09 | 2025-02-28 | シーフォー セラピューティクス, インコーポレイテッド | Cft7455のモルフィック形態及びその製造方法 |
| WO2024073507A1 (en) | 2022-09-28 | 2024-04-04 | Theseus Pharmaceuticals, Inc. | Macrocyclic compounds and uses thereof |
| WO2024193641A1 (zh) * | 2023-03-21 | 2024-09-26 | 上海超阳药业有限公司 | 异吲哚啉衍生物和苯并吲哚衍生物及其应用 |
| JP2026524477A (ja) | 2023-06-30 | 2026-07-22 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング | Krasの分解のためのヘテロ二官能性化合物 |
| CN122206684A (zh) | 2023-06-30 | 2026-06-12 | 默克专利有限公司 | 用于kras蛋白降解的异双功能化合物 |
| CN121620373A (zh) * | 2024-07-26 | 2026-03-06 | 上海超阳药业有限公司 | 苯并吲哚衍生物的药物组合物、制备方法及用途 |
| WO2026065268A1 (en) * | 2024-09-29 | 2026-04-02 | Biofront Ltd | Novel conjugates for protein degradation, compositions comprising the same, and methods of using the same |
| WO2026139448A1 (en) | 2024-12-23 | 2026-07-02 | Merck Patent Gmbh | Heterobifunctional compounds for the degradation of kras protein |
| CN120138159A (zh) * | 2025-04-30 | 2025-06-13 | 徐州医科大学 | Nup35基因作为胶质母细胞瘤诊断、预后及治疗靶点的应用 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2012175481A1 (en) * | 2011-06-20 | 2012-12-27 | Institut Curie | Compositions and methods for treating leukemia |
| CN111662226B (zh) * | 2015-01-28 | 2022-03-18 | 中国科学院广州生物医药与健康研究院 | 一种2-氧代-1,2-二氢苯并[cd]吲哚类化合物 |
| EP4717317A3 (en) * | 2017-06-20 | 2026-06-03 | C4 Therapeutics, Inc. | N/o-linked degrons and degronimers for protein degradation |
| CN111902141A (zh) * | 2018-03-26 | 2020-11-06 | C4医药公司 | 用于ikaros降解的羟脑苷脂结合剂 |
| US10905684B2 (en) | 2018-06-13 | 2021-02-02 | Biotheryx, Inc. | Aminoamide compounds |
| KR102947433B1 (ko) * | 2019-04-12 | 2026-04-06 | 씨4 테라퓨틱스, 인코포레이티드 | 이카로스 및 아이올로스의 트리시클릭 분해제 |
-
2021
- 2021-08-06 AU AU2021322285A patent/AU2021322285B2/en active Active
- 2021-08-06 WO PCT/US2021/045000 patent/WO2022032132A1/en not_active Ceased
- 2021-08-06 BR BR112023002225A patent/BR112023002225A2/pt unknown
- 2021-08-06 CA CA3173658A patent/CA3173658A1/en active Pending
- 2021-08-06 KR KR1020237007995A patent/KR20230049678A/ko active Pending
- 2021-08-06 MX MX2023001545A patent/MX2023001545A/es unknown
- 2021-08-06 CN CN202180066994.5A patent/CN116194438B/zh active Active
- 2021-08-06 IL IL300373A patent/IL300373A/en unknown
- 2021-08-06 JP JP2023507879A patent/JP7846086B2/ja active Active
- 2021-08-06 TW TW110129154A patent/TWI887465B/zh active
- 2021-08-06 EP EP21853504.5A patent/EP4192450A4/en active Pending
-
2023
- 2023-02-07 US US18/106,893 patent/US20230190760A1/en active Pending
-
2026
- 2026-04-02 JP JP2026060896A patent/JP2026117027A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CA3173658A1 (en) | 2022-02-10 |
| EP4192450A1 (en) | 2023-06-14 |
| AU2021322285A1 (en) | 2023-04-13 |
| JP2023538520A (ja) | 2023-09-08 |
| KR20230049678A (ko) | 2023-04-13 |
| US20230190760A1 (en) | 2023-06-22 |
| TWI887465B (zh) | 2025-06-21 |
| IL300373A (en) | 2023-04-01 |
| MX2023001545A (es) | 2023-05-03 |
| JP2026117027A (ja) | 2026-07-14 |
| CN116194438A (zh) | 2023-05-30 |
| AU2021322285B2 (en) | 2026-08-13 |
| JP7846086B2 (ja) | 2026-04-14 |
| WO2022032132A1 (en) | 2022-02-10 |
| CN116194438B (zh) | 2026-08-07 |
| TW202220981A (zh) | 2022-06-01 |
| EP4192450A4 (en) | 2024-08-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2023001545A (es) | Terapias ventajosas para trastornos mediados por ikaros o aiolos. | |
| MX2025003712A (es) | Degradadores triciclicos de ikaros y aiolos | |
| CR20210592A (es) | Moduladores de la vía integrada del estrés | |
| UY38685A (es) | Moduladores de la vía de tensión integrada | |
| ECSP21032861A (es) | Moduladores de profármacos de la vía de estrés integrada | |
| MX2021007146A (es) | Moduladores de la via de estres integrada. | |
| BR112022005711A2 (pt) | Métodos e composições para tratar uma doença ou transtorno | |
| BR112018013995A2 (pt) | terapia de combinação de vírus oncolítico e inibidor de ponto de verificação | |
| CL2020001742A1 (es) | Inhibidores de glicolato oxidasa para el tratamiento de enfermedades | |
| BR112019003731A2 (pt) | aplicação de pridopidina para tratamento de distonias | |
| BR112016029492A2 (pt) | método para tratamento de linfoma não hodgkin | |
| BR112017007975A2 (pt) | composições e métodos para o tratamento de disfunção das glândulas meibomianas | |
| NI202100018A (es) | Moduladores de la expresión de pnpla3 | |
| MX383462B (es) | Pridopidina para el tratamiento de las discinesias inducidas por fármacos | |
| BR112019001206A2 (pt) | anticorpos monoclonais humanizados que visam ve-ptp (hptp-ss) | |
| NI202000085A (es) | Moduladores de la expresión de apol1 | |
| BR112018000542A2 (pt) | composições de irna de transtirretina (ttr) e métodos de uso das mesmas para o tratamento ou prevenção de doenças associadas à ttr | |
| MX2022009762A (es) | Moduladores del purinorreceptor 3 p2x (p2x3). | |
| MX2019007892A (es) | Compuestos inhibidores de metaloenzimas. | |
| BR112022009710A2 (pt) | Terapia de combinação compreendendo um inibidor de alk2 e um inibidor de jak2 | |
| CL2025000063A1 (es) | Anticuerpos anti-abeta | |
| MX2020009147A (es) | Moduladores de la expresion de irf4. | |
| BR112021014566A2 (pt) | Moduladores de gpr35 | |
| CO2023000557A2 (es) | Anticuerpos y métodos para tratar enfermedades asociadas a claudina | |
| CL2022000294A1 (es) | Composiciones biofarmacéuticas y procedimientos conexos. |